- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Akums Drugs and Pharmaceuticals has received a compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, confirming that all securities related to dematerialization for the quarter ending December 31, 2024, have been processed appropriately. Notably, there were no requests received for dematerialization during this period. This compliance reassures investors about the integrity of the company’s share transaction processes. While the absence of demat requests indicates stability, it might reflect a cautious sentiment among shareholders regarding their investment activity.
All announcements from Akums Drugs and Pharmaceuticals Limited